Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. more
Time Frame | PHVS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 20.04% | -0.32% | 0.48% |
1-Month Return | 4.37% | -2.79% | 3.02% |
3-Month Return | 16.03% | 2% | 2.69% |
6-Month Return | 2.38% | 10.22% | 15.17% |
1-Year Return | 10.82% | 16.53% | 33.06% |
3-Year Return | 37.02% | 20.26% | 29.62% |
5-Year Return | -25.86% | 67.2% | 94.46% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 547.41 | - | 80.46K | 150.19K | 252.27K | [{"date":"2019-12-31","value":0.22,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":31.89,"profit":true},{"date":"2022-12-31","value":59.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (547.41) | - | (80.46K) | (150.19K) | (252.27K) | [{"date":"2019-12-31","value":-54741,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-8045600,"profit":false},{"date":"2022-12-31","value":-15018600,"profit":false},{"date":"2023-12-31","value":-25227100,"profit":false}] |
Gross Margin | (Infinity%) | - | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 8.01M | 25.01M | 54.14M | 86.71M | 96.91M | [{"date":"2019-12-31","value":8.27,"profit":true},{"date":"2020-12-31","value":25.8,"profit":true},{"date":"2021-12-31","value":55.86,"profit":true},{"date":"2022-12-31","value":89.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.99M) | (25.01M) | (65.90M) | (86.74M) | (96.91M) | [{"date":"2019-12-31","value":-799340000,"profit":false},{"date":"2020-12-31","value":-2501280000,"profit":false},{"date":"2021-12-31","value":-6589909500,"profit":false},{"date":"2022-12-31","value":-8673775700,"profit":false},{"date":"2023-12-31","value":-9691362000,"profit":false}] |
Total Non-Operating Income/Expense | - | (1.15M) | 22.96M | 11.05M | (2.70M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":48.11,"profit":true},{"date":"2023-12-31","value":-11.76,"profit":false}] |
Pre-Tax Income | (8.03M) | (26.07M) | (42.66M) | (75.65M) | (99.83M) | [{"date":"2019-12-31","value":-802716200,"profit":false},{"date":"2020-12-31","value":-2606895500,"profit":false},{"date":"2021-12-31","value":-4266066200,"profit":false},{"date":"2022-12-31","value":-7565347000,"profit":false},{"date":"2023-12-31","value":-9982626200,"profit":false}] |
Income Taxes | 16.88K | (83.25K) | 70.12K | 679.09K | 1.05M | [{"date":"2019-12-31","value":1.61,"profit":true},{"date":"2020-12-31","value":-7.94,"profit":false},{"date":"2021-12-31","value":6.69,"profit":true},{"date":"2022-12-31","value":64.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | (25.99M) | (42.73M) | (76.33M) | (100.88M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2598570400,"profit":false},{"date":"2021-12-31","value":-4273077900,"profit":false},{"date":"2022-12-31","value":-7633255700,"profit":false},{"date":"2023-12-31","value":-10087506700,"profit":false}] |
Income From Continuous Operations | (8.03M) | (25.99M) | (42.73M) | (76.33M) | (107.32M) | [{"date":"2019-12-31","value":-802716200,"profit":false},{"date":"2020-12-31","value":-2598570400,"profit":false},{"date":"2021-12-31","value":-4273077900,"profit":false},{"date":"2022-12-31","value":-7633255700,"profit":false},{"date":"2023-12-31","value":-10732407300,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.04M) | (25.99M) | (42.73M) | (76.33M) | (100.88M) | [{"date":"2019-12-31","value":-804404300,"profit":false},{"date":"2020-12-31","value":-2598570400,"profit":false},{"date":"2021-12-31","value":-4273077900,"profit":false},{"date":"2022-12-31","value":-7633255700,"profit":false},{"date":"2023-12-31","value":-10087500000,"profit":false}] |
EPS (Diluted) | - | (3.45) | (3.60) | (2.36) | (3.20) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-344.99,"profit":false},{"date":"2021-12-31","value":-360,"profit":false},{"date":"2022-12-31","value":-236,"profit":false},{"date":"2023-12-31","value":-320,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PHVS | |
---|---|
Cash Ratio | 18.05 |
Current Ratio | 18.45 |
Quick Ratio | 18.45 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PHVS | |
---|---|
ROA (LTM) | -26.79% |
ROE (LTM) | -45.05% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PHVS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PHVS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.04 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Pharvaris BV (PHVS) share price today is $21.5
Yes, Indians can buy shares of Pharvaris BV (PHVS) on Vested. To buy Pharvaris BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Pharvaris BV (PHVS) via the Vested app. You can start investing in Pharvaris BV (PHVS) with a minimum investment of $1.
You can invest in shares of Pharvaris BV (PHVS) via Vested in three simple steps:
The 52-week high price of Pharvaris BV (PHVS) is $33. The 52-week low price of Pharvaris BV (PHVS) is $15.
The price-to-earnings (P/E) ratio of Pharvaris BV (PHVS) is
The price-to-book (P/B) ratio of Pharvaris BV (PHVS) is 3.04
The dividend yield of Pharvaris BV (PHVS) is 0.00%
The market capitalization of Pharvaris BV (PHVS) is $1.12B
The stock symbol (or ticker) of Pharvaris BV is PHVS